DelveInsight’s “Retinal Vein Occlusion Pipeline Insight 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It covers the Retinal Vein Occlusion pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Retinal Vein Occlusion pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Retinal Vein Occlusion Treatment Landscape. Click here to read more @ Retinal Vein Occlusion Pipeline Outlook

Key Takeaways from the Retinal Vein Occlusion Pipeline Report

• On 03 October 2025, EyeBiotech Ltd. announced a study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of EYE103 via IVT or a high dose of EYE103 via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor’s discretion.
• DelveInsight’s Retinal Vein Occlusion Pipeline analysis depicts the space with 15+ active players working to develop 15+ pipeline therapies.
• The leading Retinal Vein Occlusion Companies such as Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.
• Promising Retinal Vein Occlusion Pipeline Therapies include Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham treatment, Aflibercept (Eylea, BAY86-5321), Macular Laser Photocoagulation, Faricimab, Aflibercept, and others.

For further information, refer to the detailed Retinal Vein Occlusion Drugs Launch, Drugs Developmental Activities, and News, click here @ Retinal Vein Occlusion Ongoing Clinical Trial Analysis

The Retinal Vein Occlusion Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Retinal Vein Occlusion Pipeline Report also highlights the unmet needs with respect to the Retinal Vein Occlusion.

Retinal Vein Occlusion Overview

Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis. Central retinal vein occlusion is further divided into two categories: non-ischemic (perfused) and ischemic (nonperfused).

Retinal Vein Occlusion Emerging Drugs

• KSI-301: Kodiak sciences

The therapeutic candidate KSI-301, currently in clinical development, is a novel anti-VEGF biologic designed to have an extended ocular half-life. Ischemia due to vein occlusion results in secretion of vascular endothelial growth factor (VEGF) that causes further vascular leakage and edema. Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with RVO. As in wet AMD, an intensive treatment frequency is required to achieve optimal outcomes with currently-approved anti-VEGFs agents. However, many patients are lost to follow up due to the frequent injections and real-world outcomes in RVO do not meet the promise shown in clinical trials. By extending the on-mechanism treatment interval, KSI-301 may relieve the high treatment burden for patients, their family members, and physicians. KSI-301 is being developed in Phase III stage of development towards a once every two months or longer treatment regimen.

• 601: Sunshine Guojian Pharmaceutical

601A is a recombinant humanized anti-VEGF monoclonal antibody for injection. The proposed main indications are age-related macular degeneration and diabetic macular edema and retinal vein occlusion; and it is currently in Phase II clinical trials.

• IBE-814: Ripple Therapeutics

IBE-814 is designed to deliver a low, consistent, efficacious dose for approximately six to nine months. The goal is to extend clinical benefit while decreasing common steroid-induced adverse events. RIPPLE-1 is a phase II, multi-center, single-masked dose-ranging study designed to evaluate the safety and efficacy of two dosage regimens of IBE-814 IVT in patients with diabetic macular edema (DME) or macular edema due to retinal vein occlusion (RVO).

Stay informed about the Retinal Vein Occlusion Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Retinal Vein Occlusion Unmet Needs

The Retinal Vein Occlusion Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Retinal Vein Occlusion with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Retinal Vein Occlusion Treatment.
• Retinal Vein Occlusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Retinal Vein Occlusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Retinal Vein Occlusion market

Retinal Vein Occlusion Companies

Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.

Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical.
• Molecule Type

Retinal Vein Occlusion Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Transform your understanding of the Retinal Vein Occlusion Pipeline! See the latest progress in drug development and clinical research @ Retinal Vein Occlusion Market Drivers and Barriers, and Future Perspectives

Scope of the Retinal Vein Occlusion Pipeline Report

• Coverage- Global
• Retinal Vein Occlusion Companies- Kodiak Sciences, Hoffman-La-Roche, iRenix Medical, Inc., Sunshine Guojian Pharmaceutical, Ripple Therapeutics, Aerpio Therapeutics, The Emmes Company, Novartis, Shanghai BDgene, AsclepiX Therapeutics, Taiwan Liposome Company, Clearside Biomedical, Gene Signal, Ocular Therapeutix, Ocuphire Pharma, Eyevensys, and others.
• Retinal Vein Occlusion Pipeline Therapies- Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321), Sham treatment, Aflibercept (Eylea, BAY86-5321), Macular Laser Photocoagulation, Faricimab, Aflibercept, and others.
• Retinal Vein Occlusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Retinal Vein Occlusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Ophthalmology Research–Access the Full Retinal Vein Occlusion Pipeline Analysis Today! @ Retinal Vein Occlusion Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Retinal Vein Occlusion: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. KSI-301: Kodiak Sciences
8. Mid Stage Products (Phase II)
9. 601: Sunshine Guojian Pharmaceutical
10. Early Stage Products (Phase I)
11. MHU650: Novartis
12. Inactive Products
13. Retinal Vein Occlusion Key Companies
14. Retinal Vein Occlusion Key Products
15. Retinal Vein Occlusion- Unmet Needs
16. Retinal Vein Occlusion- Market Drivers and Barriers
17. Retinal Vein Occlusion- Future Perspectives and Conclusion
18. Retinal Vein Occlusion Analyst Views
19. Retinal Vein Occlusion Key Companies
20. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/retinal-vein-occlusion-pipeline-insight